JP2025106418A5 - - Google Patents
Info
- Publication number
- JP2025106418A5 JP2025106418A5 JP2025063020A JP2025063020A JP2025106418A5 JP 2025106418 A5 JP2025106418 A5 JP 2025106418A5 JP 2025063020 A JP2025063020 A JP 2025063020A JP 2025063020 A JP2025063020 A JP 2025063020A JP 2025106418 A5 JP2025106418 A5 JP 2025106418A5
- Authority
- JP
- Japan
- Prior art keywords
- ophthalmic preparation
- composition according
- patient
- composition
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962928092P | 2019-10-30 | 2019-10-30 | |
| US62/928,092 | 2019-10-30 | ||
| US202063068215P | 2020-08-20 | 2020-08-20 | |
| US63/068,215 | 2020-08-20 | ||
| PCT/US2020/058411 WO2021087399A1 (en) | 2019-10-30 | 2020-10-30 | Treatment of ocular diseases using endothelin receptor antagonists |
| JP2022525291A JP7664239B2 (ja) | 2019-10-30 | 2020-10-30 | エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525291A Division JP7664239B2 (ja) | 2019-10-30 | 2020-10-30 | エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025106418A JP2025106418A (ja) | 2025-07-15 |
| JP2025106418A5 true JP2025106418A5 (https=) | 2026-04-13 |
Family
ID=75715356
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525291A Active JP7664239B2 (ja) | 2019-10-30 | 2020-10-30 | エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 |
| JP2025063020A Pending JP2025106418A (ja) | 2019-10-30 | 2025-04-07 | エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525291A Active JP7664239B2 (ja) | 2019-10-30 | 2020-10-30 | エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US20220257505A1 (https=) |
| EP (2) | EP4050997A4 (https=) |
| JP (2) | JP7664239B2 (https=) |
| CN (2) | CN114786480B (https=) |
| AU (1) | AU2020373065A1 (https=) |
| CA (1) | CA3158767A1 (https=) |
| IL (1) | IL292350A (https=) |
| MX (1) | MX2022005063A (https=) |
| WO (1) | WO2021087399A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| EP4050997A4 (en) | 2019-10-30 | 2022-11-30 | Perfuse Therapeutics, Inc. | TREATMENT OF EYE DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS |
| CA3168810A1 (en) | 2020-02-06 | 2021-08-12 | Perfuse Therapeutics, Inc. | Compositions for treatment of ocular diseases |
| CA3218398A1 (en) * | 2021-04-30 | 2022-11-03 | Perfuse Therapeutics, Inc. | Treatment of ocular diseases using endothelin receptor antagonists |
| EP4329753A4 (en) * | 2021-04-30 | 2025-02-26 | Perfuse Therapeutics, Inc. | PHARMACEUTICAL COMPOSITIONS AND INTRAVITREAL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF EYE DISEASES |
| WO2022251710A2 (en) | 2021-05-28 | 2022-12-01 | Sight Sciences, Inc. | Intraocular devices, systems, and methods |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4282793A (en) * | 1992-04-10 | 1993-11-18 | State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University | A microneedle for injection of ocular blood vessels |
| US6162927A (en) | 1994-08-19 | 2000-12-19 | Abbott Laboratories | Endothelin antagonists |
| JPH0959173A (ja) * | 1995-08-21 | 1997-03-04 | Santen Pharmaceut Co Ltd | 毛様体筋緊張緩和剤 |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| US6639082B2 (en) | 2000-10-17 | 2003-10-28 | Bristol-Myers Squibb Company | Methods for the preparation of biphenyl isoxazole sulfonamides |
| JP2004525890A (ja) * | 2001-02-02 | 2004-08-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | ピラゾロ［４，３−ｄ］ピリミジンおよびエンドセリンレセプターアンタゴニストまたはチエノピリミジンおよびエンドセリンレセプターアンタゴニストを含む医薬製剤 |
| US20030176356A1 (en) * | 2001-04-24 | 2003-09-18 | University Of North Texas Health Science Center | Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma |
| GB0122318D0 (en) * | 2001-09-14 | 2001-11-07 | Novartis Ag | Organic compounds |
| US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| US20070260203A1 (en) | 2006-05-04 | 2007-11-08 | Allergan, Inc. | Vasoactive agent intraocular implant |
| EP2545920A1 (en) * | 2007-08-22 | 2013-01-16 | Abbott GmbH & Co. KG | Therapy for complications of diabetes |
| BRPI1013904A2 (pt) * | 2009-04-30 | 2016-07-19 | Univ Midwestern | método e composição para tratar cetoacidose diabética |
| US20110082151A1 (en) | 2009-06-12 | 2011-04-07 | Auspex Pharmaceuticals, Inc. | Sulfonylurea modulators of endothelin receptor |
| KR20130050939A (ko) * | 2010-04-12 | 2013-05-16 | 가부시키가이샤 아루떼꾸 우에노 | 망막 질환의 치료 방법 및 이를 위한 안과용 조성물 |
| MX390909B (es) * | 2013-12-19 | 2025-03-21 | Tassos Georgiou | Composiciones de acidos grasos omega 3 para tratar enfermedades que implican daños al sistema nervioso. |
| ES2584534B1 (es) * | 2015-03-27 | 2017-03-13 | Retinset, S.L. | Formulación tópica oftálmica de bosentan |
| CN107921036A (zh) * | 2015-05-29 | 2018-04-17 | 优势医疗公司 | 用于减少视力丧失的组合物和方法 |
| WO2017217967A1 (en) * | 2016-06-13 | 2017-12-21 | Noveome Biotherapeutics, Inc. | Novel methods for delivering therapeutic agents to the eye via nasal passages |
| WO2018185516A1 (en) | 2017-04-05 | 2018-10-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy |
| EP3642214A2 (en) * | 2017-06-19 | 2020-04-29 | Gangadhara Ganapati | Nicotinamide riboside derivatives and their uses |
| JP2020528082A (ja) * | 2017-07-17 | 2020-09-17 | ロイズマン，キース | 加齢黄斑変性と他の眼疾患の治療用の細胞透過性ペプチドを使用する治療薬の局所送達 |
| WO2019210194A1 (en) * | 2018-04-26 | 2019-10-31 | Vitrisa Therapeutics, Inc. | Pegylated compositions for ocular use, and methods thereof |
| EP4050997A4 (en) | 2019-10-30 | 2022-11-30 | Perfuse Therapeutics, Inc. | TREATMENT OF EYE DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS |
| CA3168810A1 (en) * | 2020-02-06 | 2021-08-12 | Perfuse Therapeutics, Inc. | Compositions for treatment of ocular diseases |
| EP4329753A4 (en) | 2021-04-30 | 2025-02-26 | Perfuse Therapeutics, Inc. | PHARMACEUTICAL COMPOSITIONS AND INTRAVITREAL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF EYE DISEASES |
-
2020
- 2020-10-30 EP EP20881057.2A patent/EP4050997A4/en active Pending
- 2020-10-30 AU AU2020373065A patent/AU2020373065A1/en active Pending
- 2020-10-30 MX MX2022005063A patent/MX2022005063A/es unknown
- 2020-10-30 CA CA3158767A patent/CA3158767A1/en active Pending
- 2020-10-30 IL IL292350A patent/IL292350A/en unknown
- 2020-10-30 CN CN202080076957.8A patent/CN114786480B/zh active Active
- 2020-10-30 WO PCT/US2020/058411 patent/WO2021087399A1/en not_active Ceased
- 2020-10-30 EP EP22176530.8A patent/EP4094759A1/en active Pending
- 2020-10-30 CN CN202410236817.2A patent/CN118203574A/zh active Pending
- 2020-10-30 JP JP2022525291A patent/JP7664239B2/ja active Active
-
2022
- 2022-04-29 US US17/733,210 patent/US20220257505A1/en not_active Abandoned
- 2022-04-29 US US17/733,216 patent/US11738007B2/en active Active
-
2023
- 2023-06-30 US US18/345,514 patent/US20240189288A1/en active Pending
-
2024
- 2024-12-10 US US18/976,033 patent/US20250099435A1/en active Pending
-
2025
- 2025-04-07 JP JP2025063020A patent/JP2025106418A/ja active Pending
- 2025-11-21 US US19/397,828 patent/US20260076948A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025106418A5 (https=) | ||
| JP2025169389A5 (https=) | ||
| WO2010125416A1 (en) | Drug delivery to the anterior and posterior segments of the eye | |
| CA2718161C (en) | Drug delivery to the anterior and posterior segments of the eye using eye drops | |
| KR101689847B1 (ko) | 디플루프레드네이트를 포함하는 황반부종 치료용 점안액 | |
| US20060293270A1 (en) | Methods and compositions for treating ocular disorders | |
| CA2819628C (en) | Folic acid - ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions | |
| JP2007535552A5 (https=) | ||
| JP2010536797A5 (https=) | ||
| WO2005030221A1 (ja) | 加齢黄斑変性治療剤 | |
| RU2356519C1 (ru) | Способ антистрессовой защиты макулярной сетчатки при хирургии катаракты у больных сахарным диабетом осложненного течения | |
| JP2016121163A (ja) | 眼内でのコルチコステロイド使用に伴う眼圧の発生を減少させる方法 | |
| US20240366565A1 (en) | Use of Verteporfin to Modulate Wound Healing After an Ocular Surgical Procedure or Ocular Injury | |
| RU2367388C1 (ru) | Способ лечения сосудистых и дистрофических заболеваний глаз | |
| WO2000021531A1 (en) | Remedies for ocular diseases | |
| JP2007521285A (ja) | 眼障害の処置のためのクマリン誘導体 | |
| US12364677B2 (en) | Use of chlorogenic acid in preparation of drug for preventing and treating ocular inflammation | |
| RU2375993C2 (ru) | Способ и препарат для лечения тромбозов ретинальных вен | |
| Medeiros et al. | Effectiveness of the dexamethasone intravitreal implant for treatment of patients with diabetic macular oedema | |
| CN100353947C (zh) | 以甾体为有效成分的视网膜和脉络膜疾病治疗剂 | |
| RU2320300C1 (ru) | Способ комплексной терапии оптического неврита | |
| Kulkarni et al. | Corticosteroid therapies in the management of macular edema secondary to retinal vein occlusion | |
| KR102879076B1 (ko) | Sglt-2 억제제를 포함하는 당뇨병성 안질환 예방 또는 치료용 약학적 조성물 | |
| JP2005289814A (ja) | 近視矯正手術のための医薬 | |
| Steigerwalt Jr et al. | Ocular ischemia in high myopia treated with intravenous prostaglandin E1 |